Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-009-0866-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Cancers (Basel)
December 2024
Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Doha P.O. Box 3050, Qatar.
Background: Renal adverse drug reactions (ADRs) associated with tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) are relatively rare, and there is currently no standardized protocol for their management. Therefore, this study aimed to summarize renal ADRs related to TKIs use in CML and propose an evidence-based approach to monitor and manage these ADRs.
Methods: A systematic literature review was performed to identify renal ADRs associated with TKIs in CML.
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?
ESC Heart Fail
January 2025
Cardiology Unit, University Hospital 'Paolo Giaccone', Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy.
Aims: Knowledge of the effects of sex in cardio-oncology is limited, particularly in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML). This study aims to evaluate the influence of gender differences on the incidence of cardiovascular toxicity in patients with CML.
Methods: The study population consisted of 148 patients (45% women, mean age: 58 ± 14.
Case Report: Loeffler endocarditis as a cause of left ventricular thrombosis in young women: a case study and literature review.
Front Cardiovasc Med
December 2024
Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University, Shandong First Medical University, Shandong, China.
It is unusual for young patients without any underlying diseases to experience sudden cerebral infarction and heart failure. Here, we report a rare case of a 28-year-old female patient who presented with chest tightness and dizziness. Left ventricular thrombus formation and cardiac insufficiency were evident on echocardiogram, while multiple acute or subacute cerebral infarctions were visible on brain magnetic resonance imaging.
View Article and Find Full Text PDFCardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database.
Front Pharmacol
December 2024
Department of Clinical Pharmacology and Pharmacy, Okayama University, Okayama, Japan.
Introduction: Advances in the early detection and treatment of cancer have significantly improved the prognosis of patients with cancer. Tyrosine kinase inhibitors (TKIs) are effective targeted treatments for various malignancies that act by inhibiting kinase activity. Although these drugs share a common mechanism of action, they differ in their targeted kinases, pharmacokinetics, and side effects.
View Article and Find Full Text PDFImatinib Mesylate Causes Potential Cardiac Dysfunction in Patients With Chronic Myeloid Leukemia: the Results of a Case-control Study.
Indian J Hematol Blood Transfus
October 2024
Department of Clinical Haematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Unlike second-generation tyrosine kinase inhibitors, effects of imatinib on the cardiovascular (CV) system are debatable. The current case-control study aimed to evaluate the CV effects of imatinib in patients with chronic myeloid leukemia (CML) using non-invasive 2D-echocardiography testing. Patients with CML ≥ 13 years attending the adult haematology clinic of a tertiary care hospital in north India were prospectively enrolled over 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!